
Hector O Ventura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7118794/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Obesity and Cardiovascular Disease. Journal of the American College of Cardiology, 2009, 53, 1925-1932.	2.8	1,759
2	Hypertension and sudden death. American Journal of Medicine, 1984, 77, 18-22.	1.5	554
3	Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases. Journal of the American College of Cardiology, 2009, 54, 585-594.	2.8	518
4	Impact of Obesity and the Obesity Paradox on Prevalence and Prognosis in HeartÂFailure. JACC: Heart Failure, 2013, 1, 93-102.	4.1	463
5	Obesity and suppressed B-type natriuretic peptide levels in heart failure. Journal of the American College of Cardiology, 2004, 43, 1590-1595.	2.8	445
6	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology, 2016, 68, 161-172.	2.8	338
7	Photopheresis for the Prevention of Rejection in Cardiac Transplantation. New England Journal of Medicine, 1998, 339, 1744-1751.	27.0	304
8	Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. American Journal of Cardiology, 1984, 53, 105-108.	1.6	236
9	The Obesity Paradox, Weight Loss, and Coronary Disease. American Journal of Medicine, 2009, 122, 1106-1114.	1.5	215
10	Osler's Maneuver and Pseudohypertension. New England Journal of Medicine, 1985, 312, 1548-1551.	27.0	213
11	Update on Obesity and Obesity Paradox in Heart Failure. Progress in Cardiovascular Diseases, 2016, 58, 393-400.	3.1	199
12	Diabetic cardiomyopathy - A comprehensive updated review. Progress in Cardiovascular Diseases, 2019, 62, 315-326.	3.1	197
13	Left ventricular hypertrophy and hypertension. Progress in Cardiovascular Diseases, 2020, 63, 10-21.	3.1	184
14	Left Ventricular Geometry and Survival in Patients With Normal Left Ventricular Ejection Fraction. American Journal of Cardiology, 2006, 97, 959-963.	1.6	156
15	Diurnal Variation of Blood Pressure in Elderly Patients with Essential Hypertension. Journal of the American Geriatrics Society, 1984, 32, 896-899.	2.6	153
16	Management of cardiovascular diseases in patients with obesity. Nature Reviews Cardiology, 2018, 15, 45-56.	13.7	153
17	Obesity and cardiovascular diseases. Minerva Medica, 2017, 108, 212-228.	0.9	151
18	Racial differences in cardiac adaptation to essential hypertension determined by echocardiography indexes. Journal of the American College of Cardiology, 1983, 1, 1348-1351.	2.8	141

#	Article	IF	CITATIONS
19	Understanding the Basics of Cardiopulmonary Exercise Testing. Mayo Clinic Proceedings, 2006, 81, 1603-1611.	3.0	140
20	Clinical Impact of Left Ventricular Hypertrophy and Implications for Regression. Progress in Cardiovascular Diseases, 2009, 52, 153-167.	3.1	140
21	The Interaction of Cardiorespiratory Fitness With Obesity and the Obesity Paradox in Cardiovascular Diseases, 2017, 60, 30-44.	3.1	132
22	Improving Hypertension Control and Patient Engagement Using Digital Tools. American Journal of Medicine, 2017, 130, 14-20.	1.5	127
23	Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. American Journal of Cardiology, 2004, 94, 1475-1477.	1.6	125
24	Disparate Effects of Left Ventricular Geometry and Obesity on Mortality in Patients With Preserved Left Ventricular Ejection Fraction. American Journal of Cardiology, 2007, 100, 1460-1464.	1.6	123
25	Effects of caregiver specialty on cost and clinical outcomes following hospitalization for heart failure. American Journal of Cardiology, 1998, 82, 82-85.	1.6	119
26	Cardiac allograft vasculopathy: Current concepts. American Heart Journal, 1995, 129, 791-799.	2.7	112
27	Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. Circulation, 2020, 142, e265-e286.	1.6	107
28	Fish Oils Produce Anti-inflammatory Effects and Improve Body Weight in Severe Heart Failure. Journal of Heart and Lung Transplantation, 2006, 25, 834-838.	0.6	106
29	An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. American Journal of Cardiology, 1995, 75, 853-854.	1.6	102
30	Impact of Exercise Training and Depression on Survival in Heart Failure Due to Coronary Heart Disease. American Journal of Cardiology, 2011, 107, 64-68.	1.6	100
31	The Obesity Paradox: Impact of Obesity on the Prevalence and Prognosis of Cardiovascular Diseases. Postgraduate Medicine, 2008, 120, 34-41.	2.0	98
32	Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension. American Journal of Cardiology, 1985, 55, 1023-1026.	1.6	97
33	Impaired systemic arterial compliance in borderline hypertension. American Heart Journal, 1984, 108, 132-136.	2.7	92
34	Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. American Journal of Cardiology, 1994, 74, 1042-1046.	1.6	87
35	Body Composition and Heart Failure Prevalence and Prognosis: Getting to the Fat of the Matter in the "Obesity Paradox― Mayo Clinic Proceedings, 2010, 85, 605-608.	3.0	87
36	Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. American Journal of Cardiology, 2004, 94, 454-458.	1.6	85

#	Article	IF	CITATIONS
37	Predictive model to assess risk for cardiac allograft vasculopathy: An intravascular ultrasound study. Journal of the American College of Cardiology, 1995, 26, 1537-1544.	2.8	84
38	Left Atrial Abnormalities Indicating Diastolic Ventricular Dysfunction in Cardiopathy of Obesity. Chest, 1987, 92, 1042-1046.	0.8	83
39	Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. American Journal of Cardiology, 1997, 80, 61-64.	1.6	82
40	The Coalition to Reduce Racial and Ethnic Disparities in Cardiovascular Disease Outcomes (credo). Journal of the American College of Cardiology, 2011, 57, 245-252.	2.8	82
41	Clevidipine in acute heart failure: Results of the A Study of Blood Pressure Control in Acute Heart Failure—A Pilot Study (PRONTO). American Heart Journal, 2014, 167, 529-536.	2.7	80
42	Impact of Echocardiographic Left Ventricular Geometry on Clinical Prognosis. Progress in Cardiovascular Diseases, 2014, 57, 3-9.	3.1	78
43	Diurnal variations of cardiac rhythm, arterial pressure, and urinary catecholamines in borderline and established essential hypertension. American Heart Journal, 1982, 104, 109-114.	2.7	76
44	Prognostic Implications of Left Ventricular Hypertrophy. Progress in Cardiovascular Diseases, 2018, 61, 446-455.	3.1	75
45	The impact of mode of donor brain death on cardiac allograft vasculopathy. Journal of the American College of Cardiology, 2004, 43, 806-810.	2.8	72
46	Left Atrial Volume Index Predictive of Mortality Independent of Left Ventricular Geometry in a Large Clinical Cohort With Preserved Ejection Fraction. Mayo Clinic Proceedings, 2011, 86, 730-737.	3.0	72
47	Psychopharmacology and CardiovascularÂDisease. Journal of the American College of Cardiology, 2018, 71, 2346-2359.	2.8	72
48	The Clinical Relevance of Circulating Tumor Necrosis Factor-α in Acute Decompensated Chronic Heart Failure Without Cachexia. Chest, 1996, 110, 992-995.	0.8	71
49	Hypertension as a hemodynamic disease: The role of impedance cardiography in diagnostic, prognostic, and therapeutic decision making. American Journal of Hypertension, 2005, 18, 26-43.	2.0	70
50	Thiamine Supplementation for the Treatment of Heart Failure: A Review of the Literature. Congestive Heart Failure, 2013, 19, 214-222.	2.0	69
51	Immediate hemodynamic effects of a new calcium-channel blocking agent (nitrendipine) in essential hypertension. American Journal of Cardiology, 1983, 51, 783-786.	1.6	68
52	Left Ventricular Geometry and Mortality in Patients >70 Years of Age With Normal Ejection Fraction. American Journal of Cardiology, 2006, 98, 1396-1399.	1.6	68
53	Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation Results of a prospective, randomized multicenter trial. Journal of the American College of Cardiology, 1996, 27, 1707-1712.	2.8	61
54	Obesity Paradox, Cachexia, Frailty, and Heart Failure. Heart Failure Clinics, 2014, 10, 319-326.	2.1	58

#	Article	IF	CITATIONS
55	Role of vascular remodeling in the pathogenesis of early transplant coronary artery disease: a multicenter prospective intravascular ultrasound study. Journal of Heart and Lung Transplantation, 2001, 20, 385-392.	0.6	55
56	Left ventricular hypertrophy. Postgraduate Medicine, 1992, 91, 131-143.	2.0	54
57	Impact of Obesity on the Risk of Heart Failure and Its Prognosis. Journal of the Cardiometabolic Syndrome, 2008, 3, 155-161.	1.7	54
58	Obesity and hypertension, heart failure, and coronary heart disease-risk factor, paradox, and recommendations for weight loss. Ochsner Journal, 2009, 9, 124-32.	1.1	54
59	Obesity, Heart Disease, and Favorable Prognosis—Truth or Paradox?. American Journal of Medicine, 2007, 120, 825-826.	1.5	52
60	Home Inotropic Therapy in Advanced Heart Failure. Chest, 1997, 112, 1298-1303.	0.8	50
61	Valvular Regurgitation and Right-sided Cardiac Pressures in Heart Transplant Recipients by Complete Doppler and Color Flow Evaluation. Chest, 1993, 104, 82-87.	0.8	48
62	Exercise Capacity in Adult African-Americans Referred for Exercise Stress Testing. Chest, 2004, 126, 1962-1968.	0.8	47
63	Is Heart Failure More Prevalent in Patients With Peripheral Arterial Disease? A Meta-Analysis. Congestive Heart Failure, 2007, 13, 319-322.	2.0	45
64	Progression from Concentric Left Ventricular Hypertrophy and Normal Ejection Fraction to Left Ventricular Dysfunction. American Journal of Cardiology, 2011, 108, 992-996.	1.6	45
65	Current Perspectives on Left Ventricular Geometry in Systemic Hypertension. Progress in Cardiovascular Diseases, 2016, 59, 235-246.	3.1	45
66	Coronary stenting in cardiac allograft vasculopathy. Journal of the American College of Cardiology, 1998, 32, 1636-1640.	2.8	44
67	Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. European Journal of Heart Failure, 2016, 18, 1072-1081.	7.1	44
68	Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. American Journal of Cardiology, 2005, 95, 367-372.	1.6	43
69	Implications of obesity across the heart failure continuum. Progress in Cardiovascular Diseases, 2020, 63, 561-569.	3.1	43
70	High-density Lipoprotein Cholesterol Levels and Prognosis in Advanced Heart Failure. Journal of Heart and Lung Transplantation, 2009, 28, 876-880.	0.6	41
71	Regression of Increased Left Ventricular Mass by Antihypertensives. Drugs, 1991, 42, 945-961.	10.9	40
72	Cardiac Troponin Levels in Heart Failure. Cardiology in Review, 2004, 12, 21-25.	1.4	40

#	Article	IF	CITATIONS
73	Baseline differences in the HF-ACTION trial by sex. American Heart Journal, 2009, 158, S16-S23.	2.7	40
74	SAFETY, TOLERABILITY, AND EFFICACY OF CYCLOSPORINE MICROEMULSION IN HEART TRANSPLANT RECIPIENTS: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND COMPARISON WITH THE OIL-BASED FORMULATION OF CYCLOSPORINE???RESULTS AT 24 MONTHS AFTER TRANSPLANTATION1. Transplantation, 2001, 71, 70-78.	1.0	39
75	The Incidence, Morbidity, and Mortality of Surgical Procedures After Orthotopic Heart Transplantation. Annals of Surgery, 1997, 225, 686-694.	4.2	39
76	The independent effects of left ventricular ejection fraction on shortâ€ŧerm outcomes and resource utilization following hospitalization for heart failure. Clinical Cardiology, 1999, 22, 184-190.	1.8	38
77	Mechanical circulatory support devices in advanced heart failure: 2020 and beyond. Progress in Cardiovascular Diseases, 2020, 63, 630-639.	3.1	38
78	Usefulness of Peak Oxygen Consumption in Predicting Outcome of Heart Failure in Women Versus Men. American Journal of Cardiology, 1997, 80, 1236-1238.	1.6	37
79	Ancient Egyptian Medicine and the Concept of Heart Failure. Journal of Cardiac Failure, 2006, 12, 416-421.	1.7	36
80	The "Obesity Paradox― Chest, 2008, 134, 896-898.	0.8	36
81	Obesity Cardiomyopathy: Pathophysiologic Factors and Nosologic Reevaluation. American Journal of the Medical Sciences, 2016, 352, 219-222.	1.1	36
82	Micronutrients in Chronic Heart Failure. Current Heart Failure Reports, 2013, 10, 46-53.	3.3	35
83	The Obesity Paradox in Heart Failure. JACC: Heart Failure, 2015, 3, 927-930.	4.1	35
84	Advances in mechanical circulatory support: Year in review. Journal of Heart and Lung Transplantation, 2011, 30, 487-493.	0.6	34
85	Usefulness of B-Type Natriuretic Peptide as a Predictor of Treatment Outcome in Pulmonary Arterial Hypertension. Congestive Heart Failure, 2004, 10, 221-225.	2.0	33
86	Impact of Obesity on Outcomes in Myocardial Infarction. Journal of the American College of Cardiology, 2011, 58, 2651-2653.	2.8	32
87	Racial/Ethnic Differences in B-Type Natriuretic Peptide Levels and Their Association With Care and Outcomes Among Patients Hospitalized With Heart Failure. JACC: Heart Failure, 2013, 1, 345-352.	4.1	32
88	Heterogeneity of Cardiac Allograft Vasculopathy: Clinical Insights From Coronary Angioscopy. Journal of the American College of Cardiology, 1997, 29, 1339-1344.	2.8	31
89	Assessment of intracoronary morphology in cardiac transplant recipients by angioscopy and intravascular ultrasound. American Journal of Cardiology, 1993, 72, 805-809.	1.6	30
90	Study of Arterial and Autonomic Effects of Cyclosporine in Humans. Hypertension, 2000, 35, 1258-1263.	2.7	30

#	Article	IF	CITATIONS
91	Hypertension and Cardiac Failure in its Various Forms. Medical Clinics of North America, 2009, 93, 665-680.	2.5	30
92	Muscling up to improve heart failure prognosis. European Journal of Heart Failure, 2018, 20, 1588-1590.	7.1	30
93	Association of Left Ventricular Geometry With Left Atrial Enlargement in Patients With Preserved Ejection Fraction. Congestive Heart Failure, 2012, 18, 4-8.	2.0	28
94	A perspective on reâ€evaluating digoxin's role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile. European Journal of Heart Failure, 2014, 16, 483-493.	7.1	28
95	Implications for the vascular surgeon with prolonged (3 to 89 days) intraaortic balloon pump counterpulsation. Journal of Vascular Surgery, 1997, 26, 511-516.	1.1	27
96	Value of Weight Reduction in Patients with Cardiovascular Disease. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 21-35.	0.9	27
97	Race and Ethnicity in HeartÂFailure. Journal of the American College of Cardiology, 2021, 78, 2589-2598.	2.8	27
98	CYCLOSPORINE-INDUCED HYPERTENSION IN CARDIAC TRANSPLANTATION. Medical Clinics of North America, 1997, 81, 1347-1357.	2.5	26
99	Relationship Among Epicardial Coronary Disease, Tissue Myocardial Perfusion, and Survival in Heart Transplantation. Journal of Heart and Lung Transplantation, 2005, 24, 1019-1025.	0.6	26
100	Usefulness of Heart Rate as an Independent Predictor for Survival After Heart Transplantation. American Journal of Cardiology, 2009, 103, 1290-1294.	1.6	26
101	Nutritional Assessment in Heart Failure Patients. Congestive Heart Failure, 2011, 17, 199-203.	2.0	25
102	Metabolic Syndrome and Heart Failure—The Risk, Paradox, and Treatment. Current Hypertension Reports, 2011, 13, 142-148.	3.5	25
103	Using the Minimally Invasive Impella 5.0 via the Right Subclavian Artery Cutdown for Acute on Chronic Decompensated Heart Failure as a Bridge to Decision. Ochsner Journal, 2016, 16, 210-6.	1.1	25
104	Lipid-Lowering Therapy and Long-Term Survival in Heart Transplantation. American Journal of Cardiology, 1997, 80, 802-805.	1.6	24
105	The prognostic implications of outpatient diuretic dose in heart failure. International Journal of Cardiology, 1999, 71, 219-225.	1.7	24
106	An update on pharmacotherapies in diabetic dyslipidemia. Progress in Cardiovascular Diseases, 2019, 62, 334-341.	3.1	24
107	Disparate Effects of Metabolically Healthy Obesity in Coronary Heart Disease and Heart Failure. Journal of the American College of Cardiology, 2014, 63, 1079-1081.	2.8	23
108	Immediate hemodynamic effects of urapidil in patients with essential hypertension. American Journal of Cardiology, 1985, 55, 722-725.	1.6	22

#	Article	IF	CITATIONS
109	De novo appearance of a myocardial bridge in heart transplant: Assessment by intravascular ultrasonography, Doppler, and angioscopy. American Heart Journal, 1993, 126, 453-456.	2.7	22
110	The Bi-directional Impact of Two Chronic Illnesses: Heart Failure and Diabetes – A review of the Epidemiology and Outcomes. Cardiac Failure Review, 2015, 1, 8.	3.0	22
111	Adipose Composition and HeartÂFailureÂPrognosis. Journal of the American College of Cardiology, 2017, 70, 2750-2751.	2.8	22
112	Cardiac adaptation to obesity and hypertension after heart transplantation. Journal of the American College of Cardiology, 1992, 19, 55-59.	2.8	21
113	Is all intimal proliferation created equal in cardiac allograft vasculopathy? The quantity–quality paradox. Journal of Heart and Lung Transplantation, 2003, 22, 118-123.	0.6	21
114	Bloodletting as a Cure For Dropsy: Heart Failure Down the Ages. Journal of Cardiac Failure, 2005, 11, 247-252.	1.7	20
115	Analyzing the Weight of Evidence on the Obesity Paradox and Heart Failure—Is There a Limit to the Madness?. Congestive Heart Failure, 2013, 19, 158-159.	2.0	20
116	Impedance Cardiography: Noninvasive Measurement of Cardiac Stroke Volume and Thoracic Fluid Content. Congestive Heart Failure, 2000, 6, 56-59.	2.0	19
117	Untangling the heavy cardiovascular burden of obesity. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 428-429.	3.3	19
118	Weighing in on Obesity and the Obesity Paradox in Heart Failure. Journal of Cardiac Failure, 2011, 17, 381-383.	1.7	19
119	Effects of Left Ventricular Geometry and Obesity on Mortality in Women With Normal Ejection Fraction. American Journal of Cardiology, 2014, 113, 877-880.	1.6	19
120	New Concepts in Hypertension Management: A Population-Based Perspective. Progress in Cardiovascular Diseases, 2016, 59, 289-294.	3.1	19
121	Arterial Compliance in Systolic Hypertension. Clinical and Experimental Hypertension, 1982, 4, 1037-1044.	0.3	18
122	Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant lipid registry. American Journal of Cardiology, 1996, 78, 532-535.	1.6	18
123	Relation Between Left Ventricular Geometry and Transmural Dispersion of Repolarization. American Journal of Cardiology, 2005, 96, 952-955.	1.6	18
124	Obesity, Hypertension, and the Heart. Journal of the Cardiometabolic Syndrome, 2008, 3, 168-172.	1.7	18
125	Working group 4: International medical graduates and the cardiology workforce. Journal of the American College of Cardiology, 2004, 44, 245-251.	2.8	17
126	Early recognition and treatment of hypertensive heart disease. Current Opinion in Cardiology, 2005, 20, 282-289.	1.8	17

#	Article	IF	CITATIONS
127	Risks and Benefits of Weight Loss in Heart Failure. Heart Failure Clinics, 2015, 11, 125-131.	2.1	17
128	Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation. Current Problems in Cardiology, 2017, 42, 198-225.	2.4	17
129	Heparin-Induced Hyperkalemia. Southern Medical Journal, 1987, 80, 1450-1451.	0.7	17
130	Giovanni Battista Morgagni and the foundation of modern medicine. Clinical Cardiology, 2000, 23, 792-794.	1.8	16
131	Body habitus in heart failure: understanding the mechanisms and clinical significance of the obesity paradox. Future Cardiology, 2016, 12, 639-653.	1.2	16
132	Management of Cardiac Allograft Vasculopathy by Transmyocardial Laser Revascularization. American Journal of Cardiology, 1997, 80, 224-225.	1.6	15
133	Desperate diseases, desperate measures: Tackling malignant hypertension in the 1950s. American Heart Journal, 2001, 142, 197-203.	2.7	15
134	Insights into ventricular repolarization abnormalities in cardiac allograft vasculopathy. American Journal of Cardiology, 2001, 87, 367-368.	1.6	15
135	Coenzyme Q10 and Utility in Heart Failure: Just Another Supplement?. Current Heart Failure Reports, 2016, 13, 190-195.	3.3	15
136	Interactions of hypertension, obesity, left ventricular hypertrophy, and heart failure. Current Opinion in Cardiology, 2021, 36, 453-460.	1.8	15
137	Impact of left ventricular geometry on prognosis-a review of ochsner studies. Ochsner Journal, 2008, 8, 11-7.	1.1	15
138	THE SIGNAL-AVERAGED ELECTROCARDIOGRAM IN CARDIAC TRANSPLANTATION. Transplantation, 1992, 53, 124-127.	1.0	14
139	Allograft aortopathy: An in vivo study of donor aorta involvement in cardiac allograft vasculopathy. American Heart Journal, 1997, 133, 698-702.	2.7	14
140	Bridging Patients to Cardiac Transplantation. Congestive Heart Failure, 2000, 6, 238-243.	2.0	14
141	Fragmented QRS Complexes—A Novel but Underutilized Electrocardiograhic Marker of Heart Disease. Critical Pathways in Cardiology, 2013, 12, 181-183.	0.5	14
142	Impact of comorbidities in hypertension. Current Opinion in Cardiology, 2016, 31, 374-375.	1.8	14
143	Pharmacologic Therapy for Heart Failure With Reduced Ejection Fraction: Closing the Gap Between Clinical Guidelines and Practice. Progress in Cardiovascular Diseases, 2017, 60, 187-197.	3.1	14
144	Percutaneous Coronary Angioscopy: Applications in Interventional Cardiology. Journal of Interventional Cardiology, 1993, 6, 61-68.	1.2	13

#	Article	IF	CITATIONS
145	Impedance Cardiography: A Bridge Between Research and Clinical Practice in the Treatment of Heart Failure. Congestive Heart Failure, 2000, 6, 94-102.	2.0	13
146	Geographic variations of acute heart failure syndromes. American Heart Journal, 2011, 162, 1-2.	2.7	13
147	Observations on the blood pressure paradox in heart failure. European Journal of Heart Failure, 2017, 19, 843-845.	7.1	13
148	Arterial hypertension after orthotopic cardiac transplantation. Journal of the American College of Cardiology, 1990, 15, 1102-1103.	2.8	12
149	Historical perspectives on cardiac transplantation: the past as prologue to challenges for the 21st century. Current Opinion in Cardiology, 2001, 16, 118-123.	1.8	12
150	Pathophysiology of Pulmonary Arterial Hypertension. Seminars in Cardiothoracic and Vascular Anesthesia, 2007, 11, 104-109.	1.0	12
151	Regional differences in use and outcomes of left ventricular assist devices: Insights from the Interagency Registry for Mechanically Assisted Circulatory Support Registry. Journal of Heart and Lung Transplantation, 2015, 34, 912-920.	0.6	12
152	Future pharmacological therapy in hypertension. Current Opinion in Cardiology, 2018, 33, 408-415.	1.8	12
153	The Obesity Paradox and Discrepancy Between Peak Oxygen Consumption and Heart Failure Prognosis?It's All in the Fat. Congestive Heart Failure, 2007, 13, 177-180.	2.0	11
154	Antihypertensive Therapy for Prehypertension. JAMA - Journal of the American Medical Association, 2011, 305, 940.	7.4	11
155	Body Composition and AdvancedÂHeartÂFailure Therapy. JACC: Heart Failure, 2016, 4, 769-771.	4.1	11
156	Bariatric Surgery in Patients with Obesity and Ventricular Assist Devices Considered for Heart Transplantation: Systematic Review and Individual Participant Data Meta-analysis. Journal of Cardiac Failure, 2021, 27, 338-348.	1.7	11
157	Osborn Waves in Sepsis. Southern Medical Journal, 2006, 99, 1302-1303.	0.7	10
158	Comparison of Cardiac and Peripheral Arterial Stiffening and Ventriculovascular Uncoupling in Patients With Uncomplicated Hypertension Versus Patients With Hypertension After Heart Transplantation. American Journal of Cardiology, 2006, 98, 789-792.	1.6	10
159	Use of Body Fatness Cutoff Points–Reply–I. Mayo Clinic Proceedings, 2010, 85, 1057-1058.	3.0	10
160	Clinical Characteristics, Treatment Patterns and Outcomes of Hispanic Hypertensive Patients. Progress in Cardiovascular Diseases, 2014, 57, 244-252.	3.1	10
161	Laparoscopic Sleeve Gastrectomy in Patients with Obesity and Ventricular Assist Devices: a Comprehensive Outcome Analysis. Obesity Surgery, 2021, 31, 884-890.	2.1	10
162	Fish oil in primary and secondary cardiovascular prevention. Ochsner Journal, 2008, 8, 49-60.	1.1	10

#	Article	IF	CITATIONS
163	Alton Ochsner, MD: Physician. Ochsner Journal, 2002, 4, 48-52.	1.1	10
164	Colles-Stokes Contributions to the Concept of Heart Failure. American Journal of Cardiology, 1998, 81, 1470-1473.	1.6	9
165	Mitral inflow and pulmonary venous Doppler measurements do not predict pulmonary capillary wedge pressure in heart transplant recipients. American Heart Journal, 1998, 135, 641-646.	2.7	9
166	Changing our Approach to Stage D Heart Failure. Progress in Cardiovascular Diseases, 2017, 60, 205-214.	3.1	9
167	Treatment of heart failure according to William Stokes: The enchanted mercury. Journal of Cardiac Failure, 2001, 7, 277-282.	1.7	8
168	Valvular heart disease and pregnancy. Postgraduate Medicine, 2001, 110, 69-88.	2.0	8
169	Benefits of inpatient initiation of β-blockers. American Heart Journal, 2004, 148, 944-950.	2.7	8
170	Obesity, Age, and Cardiac Risk. Current Cardiovascular Risk Reports, 2011, 5, 128-137.	2.0	8
171	Effects of Obesity and Weight Changes on Cardiac and Vascular Structure and Function. JACC: Heart Failure, 2014, 2, 509-511.	4.1	8
172	Observations and Reflections on the Burden ofÂHospitalizations for Heart Failure. Mayo Clinic Proceedings, 2017, 92, 175-178.	3.0	8
173	When good intentions turn bad: A need for course correction. Journal of Heart and Lung Transplantation, 2020, 39, 5-6.	0.6	8
174	Left ventricular adaptation to obesity. American Journal of Cardiology, 1982, 49, 977.	1.6	7
175	Metabolic parameters derived from cardiopulmonary stress testing for prediction of prognosis in patients with heart failure: the ochsner experience. Ochsner Journal, 2009, 9, 46-53.	1.1	7
176	Rudolph virchow and cellular pathology. Clinical Cardiology, 2000, 23, 550-552.	1.8	6
177	The Interaction of Vascular Stiffness and Cardiovascular Events in Women. Chest, 2005, 127, 1477-1480.	0.8	6
178	New Data on the Clinical Impact of Exercise Training, Fish Oils, and Statins in Heart Failure. Physician and Sportsmedicine, 2009, 37, 22-28.	2.1	6
179	Antihypertensive therapy versus alternative therapeutic options for prehypertension: an evidence-based approach. Future Cardiology, 2012, 8, 115-122.	1.2	6
180	Clinical Implications of Weight Loss in Heart Failure. Journal of Cardiac Failure, 2014, 20, 190-192.	1.7	6

#	Article	IF	CITATIONS
181	Treatment of the hypertensive patient with microvascular angina. Current Opinion in Cardiology, 1999, 14, 370.	1.8	6
182	Dietary intake of nuts and cardiovascular prognosis. Ochsner Journal, 2009, 9, 32-6.	1.1	6
183	Robert James Graves and the cardiovascular responses to postural changes in heart failure. American Journal of Cardiology, 2000, 85, 1503-1506.	1.6	5
184	Is heart failure with preserved systolic function an overlooked enigma?. Current Cardiology Reports, 2002, 4, 187-193.	2.9	5
185	Beta-Blocker Therapy and Severe Heart Failure: Myth or Reality?. Congestive Heart Failure, 2003, 9, 197-202.	2.0	5
186	White Coat Hypertension and Sleep Apnea. Chest, 2004, 125, 805-807.	0.8	5
187	Hypertension and heart failure: Diagnosis and management. Current Hypertension Reports, 2006, 8, 185-190.	3.5	5
188	Dickinson Woodruff Richards and Cardiac Catheterization. Clinical Cardiology, 2007, 30, 420-421.	1.8	5
189	Device Therapy for Heart Failure. American Journal of Cardiovascular Drugs, 2008, 8, 147-153.	2.2	5
190	Natriuretic Peptides as Markers of Cardiovascular Risk: The Story Continues. Mayo Clinic Proceedings, 2011, 86, 1143-1145.	3.0	5
191	Health Literacy: An Important Clinical Tool in HeartÂFailure. Mayo Clinic Proceedings, 2018, 93, 1-3.	3.0	5
192	Hypertension. Current Opinion in Cardiology, 2018, 33, 375-376.	1.8	5
193	Editorial. Current Opinion in Cardiology, 2019, 34, 329-330.	1.8	5
194	Impact of Preinfection Left Ventricular Ejection Fraction on Outcomes in COVID-19 Infection. Current Problems in Cardiology, 2021, 46, 100845.	2.4	5
195	The Impact of Obesity in Heart Failure. Cardiology Clinics, 2022, 40, 209-218.	2.2	5
196	Induction Immunosuppression with the Monoclonal Antibody OKT3 After Cardiac Transplantation. American Journal of the Medical Sciences, 1993, 306, 16-19.	1.1	4
197	Recent developments in microvascular angina. Current Atherosclerosis Reports, 2001, 3, 149-155.	4.8	4
198	Nuggets, Pearls, and Vignettes of Master Heart Failure Clinicians. Congestive Heart Failure, 2001, 7, 245-249.	2.0	4

#	Article	IF	CITATIONS
199	The Conundrum of Sleep Breathing Disorders in Heart Failure. Chest, 2003, 123, 1332-1334.	0.8	4
200	Electronic home monitoring reduces medical resource utilization in chronic heart failure: a prospective investigation of the HomMed-sentry telemonitoring system. Journal of Cardiac Failure, 2004, 10, S110-S111.	1.7	4
201	Should We Start Prescribing Omega-3 Polyunsaturated Fatty Acids in Chronic Heart Failure?. Current Heart Failure Reports, 2012, 9, 8-13.	3.3	4
202	Aldosterone Antagonists: Evidenceâ€Based Yet Underutilized Effective Heart Failure Therapy. Congestive Heart Failure, 2013, 19, 105-106.	2.0	4
203	Heart Failure in Ethnic Minorities. JACC: Heart Failure, 2014, 2, 400-402.	4.1	4
204	Effect of patiromer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials. Progress in Cardiovascular Diseases, 2020, 63, 656-661.	3.1	4
205	HeartÂFailure With PreservedÂEjectionÂFraction. Journal of the American College of Cardiology, 2020, 75, 255-257.	2.8	4
206	Obesity Is a Heavy Load in Cardiogenic Shock and Mechanical Circulation. Circulation: Heart Failure, 2021, 14, e008300.	3.9	4
207	New aspects in the management of hypertension in the digital era. Current Opinion in Cardiology, 2021, 36, 398-404.	1.8	4
208	Management of Patients Admitted with Acute Decompensated Heart Failure. Ochsner Journal, 2015, 15, 284-9.	1.1	4
209	Going home. Postgraduate Medicine, 1993, 93, 159-160.	2.0	3
210	ls It Constrictive Pericarditis or Restrictive Cardiomyopathy? A Systematic Approach. Congestive Heart Failure, 2004, 10, 309-312.	2.0	3
211	Destination therapy in late-stage heart failure. Coronary Artery Disease, 2004, 15, 87-90.	0.7	3
212	Adjunctive Sildenafil for the Treatment of Pulmonary Hypertension After Mitral Valve Replacement. Congestive Heart Failure, 2006, 12, 347-348.	2.0	3
213	Exercise Training as Treatment of Depression in Heart Failure. Journal of the American College of Cardiology, 2012, 59, 291.	2.8	3
214	Impact of Obesity on the Prevalence and Prognosis of Heart Failure—lt Is Not Always Just Black and White. Journal of Cardiac Failure, 2016, 22, 598-599.	1.7	3
215	The importance of achieving blood pressure control, what is the target?. Current Opinion in Cardiology, 2017, 32, 363-364.	1.8	3
216	Comprehensive Heart Failure Management. Progress in Cardiovascular Diseases, 2017, 60, 169-170.	3.1	3

#	Article	IF	CITATIONS
217	Improving Provider Adherence to Guideline Recommendations in Heart Failure. Current Heart Failure Reports, 2018, 15, 350-356.	3.3	3
218	Prognostic value of cardiopulmonary exercise test after heart transplantation. Clinical Transplantation, 2021, 35, e14387.	1.6	3
219	FGF23 predicts outcomes in heart failure but questions remain unanswered. International Journal of Cardiology, 2021, 338, 145-146.	1.7	3
220	The comprehensive management of anticoagulation: ochsner coumadin clinic. Ochsner Journal, 2002, 4, 37-40.	1.1	3
221	Guy Alvin Caldwell, MD: Physician and Administrator. Ochsner Journal, 2002, 4, 112-4.	1.1	3
222	Benzocaine induced methemoglobinemia: a potentially fatal complication of transesophageal echocardiography. Ochsner Journal, 2003, 5, 34-5.	1.1	3
223	Modulation of tumor necrosis factor \hat{I}_{\pm} in advanced heart failure with cachexia is associated with anabolic effects. Journal of the American College of Cardiology, 1996, 27, 70-71.	2.8	2
224	On-Line Myocardial Tissue Characterization with a New Commercially Produced Software. Echocardiography, 1996, 13, 271-279.	0.9	2
225	Bridge to ß Blockade in Severe Heart Failure: The Use of Phosphodiesterase Inhibitors. Congestive Heart Failure, 2000, 6, 164-166.	2.0	2
226	Edward D. Frohlich, MD A Conversation About Hypertension: From Bedside to Bench and Return. Congestive Heart Failure, 2002, 8, 321-330.	2.0	2
227	Treatment of hypertension for patients with diastolic dysfunction. Current Opinion in Cardiology, 2003, 18, 272-277.	1.8	2
228	Heart Failure in Hispanic Patients: Coming Together?. Congestive Heart Failure, 2010, 16, 187-188.	2.0	2
229	Nitroprusside and the Treatment of Hypertension. Congestive Heart Failure, 2011, 17, 49-49.	2.0	2
230	Disparities in Women with Heart Failure. Current Cardiovascular Risk Reports, 2011, 5, 261-265.	2.0	2
231	Developments in Heart Failure 2011. Congestive Heart Failure, 2012, 18, 112-126.	2.0	2
232	Reply. JACC: Heart Failure, 2016, 4, 234-235.	4.1	2
233	Rehabilitating cardiac rehabilitation after heart transplantation. Journal of Heart and Lung Transplantation, 2018, 37, 437-438.	0.6	2
234	The Impact of Mediators of Health Literacy on Clinical Outcomes in Cardiovascular Diseases. Mayo Clinic Proceedings, 2018, 93, 1700-1702.	3.0	2

#	Article	IF	CITATIONS
235	Management of resistant hypertension. Current Opinion in Cardiology, 2019, 34, 367-375.	1.8	2
236	HDL and Heart Failure Regulation. Journal of the American College of Cardiology, 2019, 73, 187-189.	2.8	2
237	Second Consensus on Treatment of Patients Recently Diagnosed With Mild Hypertension and Low Cardiovascular Risk. Current Problems in Cardiology, 2020, 45, 100653.	2.4	2
238	Laparoscopic Sleeve Gastrectomy in Patients with Ventricular Assist Devices, Beyond Just Bridging to Heart Transplantation. Obesity Surgery, 2020, 30, 5123-5124.	2.1	2
239	Triple Antithrombotic Therapy in Patients With Left Ventricular Assist Devices. Current Problems in Cardiology, 2021, 47, 100940.	2.4	2
240	A Historical Look at Hypertension: Celebrating 100 Years with the Southern Medical Association. Southern Medical Journal, 2006, 99, 1412-1413.	0.7	2
241	Dean Holland Echols, MD: The Sixth Founder. Ochsner Journal, 2003, 5, 43-5.	1.1	2
242	Breaking Down the Barriers: Why the Delay in Referral for Pulmonary Arterial Hypertension?. Ochsner Journal, 2016, 16, 257-62.	1.1	2
243	The era of heart failure risk prediction models, is it time to test their utility?. International Journal of Cardiology, 2022, 352, 98-99.	1.7	2
244	Cardiac Transplantation: Clinical Aspects of Recipient Selection. Medical Clinics of North America, 1992, 76, 1196-1206.	2.5	1
245	Current issues in advanced heart failure. Medical Clinics of North America, 1992, 76, 1057-1082.	2.5	1
246	The unique management of refractory advanced systolic heart failure. Heart and Lung: Journal of Acute and Critical Care, 1997, 26, 280-288.	1.6	1
247	The AHF SCENE II Preceptorship Program: Rationale and Design of an Educational Program to Optimize Management of Advanced Heart Failure. Congestive Heart Failure, 2000, 6, 319-324.	2.0	1
248	Historical Vignettes in Heart Failure. Congestive Heart Failure, 2003, 9, 108-108.	2.0	1
249	Historical Vignettes in Heart Failure. Congestive Heart Failure, 2009, 15, 101-101.	2.0	1
250	Cardiovascular Outcomes and Angiotensin Converting Enzyme Inhibitors: Beyond Blood Pressure Control. Cardiovascular Drugs and Therapy, 2009, 23, 109-111.	2.6	1
251	Relationship Between Arterial Impedance and Concentric Remodeling in Patients With Normal Systolic Function: Impact on Prevalence and Survival. Congestive Heart Failure, 2011, 17, 283-287.	2.0	1
252	Kenneth Baughman, MD: A Personal Reflection. American Journal of Cardiology, 2011, 107, 139-140.	1.6	1

#	Article	IF	CITATIONS
253	TOTAL BILIRUBIN/ALBUMIN RATIO HAS AN INDEPENDENT AND INCREMENTAL ROLE IN PREDICTING RIGHT VENTRICULAR FAILURE AFTER LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION. Journal of the American College of Cardiology, 2013, 61, E756.	2.8	1
254	Transcatheter Potts shunt: An innovative IDEA. Journal of Heart and Lung Transplantation, 2013, 32, 388-389.	0.6	1
255	The consummate clinician. Journal of Heart and Lung Transplantation, 2014, 33, 1103.	0.6	1
256	Preface. Heart Failure Clinics, 2014, 10, xi.	2.1	1
257	Tackling cardiovascular disease in Hispanic/Latinos: Achieving 2020 Goals. American Heart Journal, 2016, 176, 125-126.	2.7	1
258	Foreword. Current Problems in Cardiology, 2016, 41, 193.	2.4	1
259	Influence of Neurohormonal Antagonists on the Association of Loop Diuretic Dose with Mortality in Patients with Heart Failure: Insights From the UNITE-HF Registry. Journal of Cardiac Failure, 2016, 22, S35.	1.7	1
260	Obesity and Prognosis in PediatricÂDilatedÂCardiomyopathy. JACC: Heart Failure, 2018, 6, 231-232.	4.1	1
261	New Guidelines, Increasing Hypertension Numbers, Resistance and Resistance to Change?. Mayo Clinic Proceedings, 2019, 94, 745-747.	3.0	1
262	We all need a yellow submarine!. Progress in Cardiovascular Diseases, 2020, 63, 389.	3.1	1
263	Feasibility and Safety of Coronary Angiography via Radial Approach in Cardiac Transplant Recipients: A Single Center Experience. Current Problems in Cardiology, 2022, 47, 100935.	2.4	1
264	Advanced heart failure and management strategies. Ochsner Journal, 2009, 9, 227-33.	1.1	1
265	Preventive cardiology and non-invasive cardiology research at the ochsner clinic foundation. Ochsner Journal, 2006, 6, 31-5.	1.1	1
266	Francis Earnest ("Duke") LeJeune, MD. Ochsner Journal, 2003, 5, 47-8.	1.1	1
267	Edgar burns. Ochsner Journal, 2002, 4, 180-2.	1.1	1
268	Curtis tyrone, MD. Ochsner Journal, 2002, 4, 245-6.	1.1	1
269	Is There an Obesity Paradox in Cardiogenic Shock?. Journal of the American Heart Association, 2022, 11,	3.7	1
270	Searching for Peter Pan. Postgraduate Medicine, 1997, 101, 22-24.	2.0	0

#	Article	IF	CITATIONS
271	Difficult Cases in Heart Failure Marc A. Silver, MD Hector O. Ventura, MD Editors. Beneficial Effects of Aldosterone Blockade in Heart Failure. Congestive Heart Failure, 2000, 6, 115-117.	2.0	0
272	Ventricular Resynchronization in Refractory Heart Failure. Congestive Heart Failure, 2000, 6, 333-336.	2.0	0
273	From new orleans to buenos aires: my meeting with dr. rené gerónimo favaloro. American Journal of Cardiology, 2001, 87, 672-673.	1.6	0
274	Raison d'Être Behind ACE Inhibitors and AT1Receptor Combinations in Chronic Heart Failure: Chemical Nuances or Clinical Significance?. Congestive Heart Failure, 2001, 7, 101-104.	2.0	0
275	Historical Vignettes in Heart Failure. Congestive Heart Failure, 2001, 7, 111-111.	2.0	0
276	The Copernicus journey. American Journal of Cardiology, 2002, 89, 783-784.	1.6	0
277	Sir Christiaan Barnard: a personal reflection. American Journal of Cardiology, 2002, 89, 782-783.	1.6	0
278	Historical Vignettes in Heart Failure. Congestive Heart Failure, 2002, 8, 92-92.	2.0	0
279	Percutaneous Transluminal Septal Myocardial Ablation in the Management of Hypertrophic Obstructive Cardiomyopathy. Congestive Heart Failure, 2003, 9, 343-346.	2.0	0
280	"Read Guyton― American Journal of Cardiology, 2004, 93, 516-517.	1.6	0
281	Obesity and B-type natriuretic peptide levels in heart failure: Reply. Journal of the American College of Cardiology, 2005, 45, 967.	2.8	0
282	Edward D. Freis-A True Pioneer. Journal of Clinical Hypertension, 2006, 8, 284-287.	2.0	0
283	Historical Vignettes in Heart Failure. Congestive Heart Failure, 2006, 12, 54-54.	2.0	0
284	H.J.C. "Jeremy―Swan, MD: In memory of his contributions to cardiovascular medicine. Catheterization and Cardiovascular Interventions, 2006, 67, 171-174.	1.7	0
285	In Memoriam Charles Wooley, MD. American Journal of Cardiology, 2008, 101, 1677-1678.	1.6	0
286	Selling Teaching Hospitals and Practice Plans: George Washington and Georgetown Universities. JAMA - Journal of the American Medical Association, 2008, 300, 2555.	7.4	0
287	Heart Failure and Cardiac Catheterization. Congestive Heart Failure, 2009, 15, 295-295.	2.0	0
288	Cardiac Carcinoid. Congestive Heart Failure, 2009, 15, 43-45.	2.0	0

17

#	Article	IF	CITATIONS
289	Exercise Training and Heart Failure in Older Adults—Dismal Failure or Not Enough Exercise?. Journal of the American Geriatrics Society, 2009, 57, 2148-2150.	2.6	0
290	Historical Vignettes in Heart Failure. Congestive Heart Failure, 2010, 16, 42-43.	2.0	0
291	Induced Hypothermia Prior to Left Ventricular Assist Device. Congestive Heart Failure, 2010, 16, 231-233.	2.0	0
292	Historical Vignettes in Heart Failure. Congestive Heart Failure, 2010, 16, 136-137.	2.0	0
293	Nitroprusside in Refractory Heart Failure. Congestive Heart Failure, 2011, 17, 157-157.	2.0	Ο
294	Do BNP Levels and Prognostic Value Vary by Race/Ethnicity in Patients Hospitalized With Heart Failure?. Journal of Cardiac Failure, 2012, 18, S80-S81.	1.7	0
295	Impact of Ethnicity and Race on Response to Angiotensin-Converting Enzyme Inhibitors in Heart Failure. Journal of Cardiac Failure, 2015, 21, 457-459.	1.7	0
296	Foreword. Current Problems in Cardiology, 2016, 41, 249.	2.4	0
297	Foreword. Current Problems in Cardiology, 2016, 41, 265.	2.4	0
298	In Memoriam Arnold M Katz, MD. American Journal of Cardiology, 2016, 117, 1996-1997.	1.6	0
299	Therapeutic Cardiorespiratory Fitness toÂPrevent and Treat Heart Failure â^—. JACC: Heart Failure, 2017, 5, 375-376.	4.1	0
300	INFLUENCE OF LOW VERSUS HIGH DOSE ON THE ASSOCIATION OF LOOP DIURECTIC AND MORTALITY IN PATIENTS WITH HEART FAILURE: INSIGHTS FROM THE UNITE-HF REGISTRY. Journal of the American College of Cardiology, 2017, 69, 710.	2.8	0
301	Foreword. Current Problems in Cardiology, 2017, 42, 172.	2.4	0
302	Hemodynamic effects of a fully magnetically levitated centrifugal-flow left ventricular assist device. Journal of Heart and Lung Transplantation, 2017, 36, 19-21.	0.6	0
303	Blood pressure and goal titration of neurohormonal antagonists: the tortoise wins again?. European Journal of Heart Failure, 2018, 20, 501-503.	7.1	0
304	John Lockwood Ochsner: Celebration of life. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1769-1771.	0.8	0
305	Edward D. Frohlich, MD. Hypertension, 2019, 74, 1229-1231.	2.7	0
306	Impact of a mentor. Progress in Cardiovascular Diseases, 2020, 63, 704-705.	3.1	0

#	Article	IF	CITATIONS
307	Laparoscopic sleeve gastrectomy in obese patients with ventricular assist devices: a data note. BMC Research Notes, 2020, 13, 439.	1.4	0
308	BMI Trends In Patients With Ventricular Assist Devices After Bariatric Surgery. Journal of Cardiac Failure, 2020, 26, S40-S41.	1.7	0
309	Editorial: Hypertension in special populations and the role in comoborbities. Current Opinion in Cardiology, 2020, 35, 341.	1.8	Ο
310	Editorial: The burden of hypertension and its management. Current Opinion in Cardiology, 2021, 36, 397.	1.8	0
311	Bulla hemorrágica rota en un paciente con un HeartMate 3 tratado con un dispositivo Amplatzer. Archivos De Cardiologia De Mexico, 2021, 91, .	0.2	0
312	Love Is the Best Doctor. Annals of Internal Medicine, 1994, 120, 890.	3.9	0
313	Use of TandemHeart as Bridge to Recovery for Antibody-Mediated Rejection in a Heart Transplant Patient. JACC: Case Reports, 2020, 2, 2358-2362.	0.6	0
314	Henry w. Ochsner, MD - the ochsner lineage in medicine. Ochsner Journal, 2007, 7, 73.	1.1	0
315	Research at ochsner clinic: highlights in its history. Ochsner Journal, 2007, 7, 74-6.	1.1	0
316	Merrill Odom Hines, MD: The Right Fellow for the Job. Ochsner Journal, 2003, 5, 30-3.	1.1	0
317	Bioethics in Practice: Quantity, but More Important, Quality of Life in Heart Failure. Ochsner Journal, 2015, 15, 216.	1.1	0
318	The Secret Trip of Dr Alton Ochsner. Ochsner Journal, 2016, 16, 116-9.	1.1	0
319	Ruptured Bullae: A Rare Cause of No-flow Alarms In Ventricular Assist Devices. Journal of Cardiac Failure, 2020, 26, S62.	1.7	0
320	Outcomes After Bariatric Surgery In Patients With Ventricular Assist Devices: Systematic Review And Individual Participant Data Meta-analysis. Journal of Cardiac Failure, 2020, 26, S53.	1.7	0
321	Understanding Heart Failure Risk in a Diverse Cohort With Human Immunodeficiency Virus Infection. Mayo Clinic Proceedings, 2022, 97, 433-435.	3.0	0
322	Emerging Comorbidities in Heart Failure. Cardiology Clinics, 2022, 40, xi-xiv.	2.2	0
323	Preimplant hyponatremia does not predict adverse outcomes in patient with left ventricular assist devices. Current Problems in Cardiology, 2022, , 101239.	2.4	0
324	Increased oxygen delivery reduced morbidity and mortality in high-risk surgery. ACP Journal Club, 1994, 120, 76.	0.1	0